JP2012524119A - C−ピラジン−メチルアミンの調製 - Google Patents
C−ピラジン−メチルアミンの調製 Download PDFInfo
- Publication number
- JP2012524119A JP2012524119A JP2012507282A JP2012507282A JP2012524119A JP 2012524119 A JP2012524119 A JP 2012524119A JP 2012507282 A JP2012507282 A JP 2012507282A JP 2012507282 A JP2012507282 A JP 2012507282A JP 2012524119 A JP2012524119 A JP 2012524119A
- Authority
- JP
- Japan
- Prior art keywords
- reaction
- diarylimine
- alkyl
- formula
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
いくつかの態様において、工程(a)において、ジアリールイミンは、反応A:
式中、R2は、C1-C10アルキルであり;(b)(a)のジアリールイミン生成物および2,3-ジクロロピラジンを塩基の存在下において共に反応させ;および(c)(b)の生成物を加水分解させてR1がHである式Iの化合物を得る。
式中、R3は、C1-C10アルキル、C3-C12シクロアルキル、アリールまたはヘテロアリールであり、これらのいずれもがハロ、オキソ、シアノ、ヒドロキシおよびC1-C10アルキルから選択される1つまたは複数の独立した置換基によって任意に置換され;およびR4は、ヒドロキシ、アルコキシ、クロロまたはイミダゾールである。
1H NMR (400 MHz, CDCl3) δ ppm 3.83 (s, 3H), 3.87 (s, 3H), 4.83 (s, 2H), 6.83-6.91 (m, 2H), 6.94 - 7.03 (m, 2H), 7.14-7.22 (m, 2H), 7.40-7.58 (m, 4H), 7.65- 7.74 (m, 2H), 7.75- 7.87 (m, 2H), 8.07-8.23 (m, 4H). 参照文献: N. Sotomayor Tetrahedron, 1994 , 50, 2207
加水分解のための代わりのアプローチにおいて、機械的撹拌器、N2入口/出口および温度計を備えた72Lの丸底フラスコに、トルエン中の上の実施例6において生成したものなどの粗製ピラジンイミン化合物などの溶液(〜30 L、29.9mol)を充填した。水(12L)および濃HCl(3.2L、32.9mol)を添加して、反応混合物を3時間の間、外界温度にて撹拌した(TLCによってモニターした)。層を分離して、水層をトルエン(15L)で抽出した。
本明細書に使用される、「アリール」という用語は、完全に共役したパイ電子系を有する6〜12炭素原子の全て炭素の単環式、二環式または多環式の基をいう。アリールの例は、フェニル、4-クロロフェニル、4-フルオロフェニル、4-ブロモフェニル、3-ニトロフェニル、2-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、4-エチルフェニル、2-メチル-3-メトキシフェニル、2,4-ジブロモフェニル、3,5-ジフルオロフェニル、3,5-ジメチルフェニル、2,4,6-トリクロロフェニル、4-メトキシフェニル、ナフチル、2-クロロナフチル、2,4-ジメトキシフェニル、4-(トリフルオロメチル)フェニルおよび2-ヨード-4-メチルフェニルを含むが、限定されない。
表1−略語
Claims (23)
- 反応Bを使用してジアリールイミンを製造する、請求項2の方法。
- R1は、フェニル、4-クロロフェニル、4-フルオロフェニル、4-ブロモフェニル、3-ニトロフェニル、2-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、4-エチルフェニル、2-メチル-3-メトキシフェニル、2,4-ジブロモフェニル、3,5-ジフルオロフェニル、3,5-ジメチルフェニル、2,4,6-トリクロロフェニル、4-メトキシフェニル、ナフチル、2-クロロナフチル、2,4-ジメトキシフェニル、4-(トリフルオロメチル)フェニル、または2-ヨード-4-メチルフェニルから選択されるアリール基であり;およびアリール基は、C1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基で任意に置換される、請求項1-3のいずれか1項の方法。
- R1は、2-、3-または4-ピリジニル、ピラジニル、2-、4-もしくは5-ピリミジニル、ピリダジニル、トリアゾリル、テトラゾリル、イミダゾリル、2-もしくは3-チエニル、2-もしくは3-フリル、ピロリル、オキサゾリル、イソオキサゾリル、チアゾリル、イソチアゾリル、オキサジアゾリル、チアジアゾリル、キノリル、イソキノリル、ベンズイミダゾリル、ベンゾトリアゾリル、ベンゾフラニルまたはベンゾチエニルから選択されるヘテロアリール基であり;およびヘテロアリール基は、C1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基で任意に置換される、請求項1-3のいずれか1項の方法。
- R1は、2-フェニルキノリンである、請求項1-3のいずれか1項の方法。
- 少なくとも約0.5molの式Iが、少なくとも約50%の方法についての全体の収率において得られる、請求項1-6のいずれか1項の方法。
- (a)のための反応溶媒は、テトラヒドロフランまたは1,4-ジオキサンを含む、請求項2-7のいずれか1項の方法。
- 反応Aを使用してジアリールイミンを製造し、かつ有機塩基およびルイス酸の存在下において実施される、請求項2または4-8のいずれか1項の方法。
- 反応Aにおける有機塩基は、トリエチルアミンまたはN-メチルモルホリンを含む、請求項9の方法。
- ルイス酸は、四塩化チタンを含む、請求項9または10の方法。
- 2,3-ジクロロピラジンとジアリールイミンの反応は、tert-ブトキシドまたは金属ヘキサメチルジシルアジドの存在下において実施される、請求項1-11のいずれか1項の方法。
- R2は、メチル、エチル、n-プロピル、イソプロピル、n-ブチル、sec-ブチル、イソブチル、tert-ブチル、n-ペンチル、イソペンチル、n-ヘキシル、n-ヘプチル、イソオクチル、ノニル、デシルから選択され、これらのいずれもがC1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基によって置換することができる、請求項13の方法。
- R2は、メチルである、請求項13の方法。
- 少なくとも約0.5molの式Iが、少なくとも約50%の方法についての全体の収率において得られる、請求項13-15のいずれか1項の方法。
- 反応Cは、トリエチルアミンまたはエチルジイソプロピルアミンの存在下において実施される、請求項13-16のいずれか1項の方法。
- (b)のための塩基は、炭酸カリウムまたは炭酸セシウムを含む、請求項13-17のいずれか1項の方法。
- 工程(b)は、約40〜60℃の温度にて実施される、請求項13-18のいずれか1項の方法。
- (c)は、水酸化カリウム、水酸化ナトリウムまたは水酸化リチウムの存在下において実施される、請求項13-18のいずれか1項の方法。
- (c)は、塩酸、トリフルオロ酢酸、酢酸または硫酸の存在下において実施される、請求項13-18のいずれか1項の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17091109P | 2009-04-20 | 2009-04-20 | |
US61/170,911 | 2009-04-20 | ||
PCT/US2010/031547 WO2010123792A1 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012524119A true JP2012524119A (ja) | 2012-10-11 |
JP2012524119A5 JP2012524119A5 (ja) | 2013-04-25 |
Family
ID=42269933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012507282A Pending JP2012524119A (ja) | 2009-04-20 | 2010-04-19 | C−ピラジン−メチルアミンの調製 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8513415B2 (ja) |
EP (1) | EP2421837A1 (ja) |
JP (1) | JP2012524119A (ja) |
KR (1) | KR20120020099A (ja) |
CN (1) | CN102405214A (ja) |
BR (1) | BRPI1016245A2 (ja) |
CA (1) | CA2752826A1 (ja) |
MX (1) | MX2011011025A (ja) |
WO (1) | WO2010123792A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005230818B2 (en) | 2004-04-02 | 2010-11-25 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
CN103214424B (zh) * | 2013-04-25 | 2015-05-13 | 兰州康寓信生物科技有限公司 | 吡嗪甲胺衍生物的合成方法 |
US9422285B2 (en) | 2013-08-08 | 2016-08-23 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof |
CA2969265A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
JP2018505885A (ja) | 2015-02-05 | 2018-03-01 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロ[1,5−a]−ピリジン−3−カルボキサミドおよびその使用 |
CN109553570A (zh) * | 2017-09-27 | 2019-04-02 | 胜兴化工(上海)有限公司 | 3-氯-5-三氟甲基-2-吡啶甲胺盐的制备方法 |
CN109182286B (zh) * | 2018-09-21 | 2021-07-30 | 泰州学院 | 一种改进的氰基还原酶及其在合成3-氯吡嗪-2甲胺中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673026A (ja) * | 1992-04-28 | 1994-03-15 | Koei Chem Co Ltd | クロロピラジン類の製造法 |
JP2006514075A (ja) * | 2002-11-20 | 2006-04-27 | バイエル・クロツプサイエンス・エス・アー | 2−アミノメチルピリジン誘導体の製造方法 |
JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
WO2007070826A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
JP2007531754A (ja) * | 2004-04-02 | 2007-11-08 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
JP2008105970A (ja) * | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
JP2914407B2 (ja) | 1991-09-11 | 1999-06-28 | 富士電機株式会社 | 自動販売機 |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
DE69734149T2 (de) | 1996-03-15 | 2006-07-06 | Astrazeneca Ab | Cinoline derivate und verwendung als heilmittel |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
HUP0201480A3 (en) | 1999-05-14 | 2009-03-30 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
BR0013219A (pt) | 1999-08-12 | 2002-04-23 | American Cyanamid Co | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto |
GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
AU2002239486A1 (en) | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
CA2436326C (en) | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
SK12002003A3 (en) | 2001-03-28 | 2004-10-05 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
RU2003134180A (ru) | 2001-05-08 | 2005-02-10 | Мерк Патент ГмбХ (DE) | Комбинированная терапия, использующая антитела к egfr и антигормональные средства |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
WO2003000187A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
CA2470088A1 (en) | 2001-12-20 | 2003-07-03 | Tularik Inc. | Identification of an amplified gene and target for drug intervention |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
JP2005530735A (ja) | 2002-04-16 | 2005-10-13 | アストラゼネカ アクチボラグ | 癌の処置のための併用療法 |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
DE10254853A1 (de) | 2002-11-25 | 2004-06-03 | Basf Ag | Verbessertes Verfahren zur Herstellung von Cyclopentenonen |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
RS20050692A (en) | 2003-03-12 | 2007-11-15 | Pfizer Production Inc., | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
RU2006143842A (ru) * | 2004-05-13 | 2008-08-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Новые замещенные тиофенкарбоксамиды, их получение и их применение в качестве лекарственных средств |
NZ551431A (en) | 2004-06-03 | 2010-04-30 | Hoffmann La Roche | Treatment with cisplatin and an EGFR-inhibitor |
EP1768982A2 (en) | 2004-06-29 | 2007-04-04 | Amgen Inc. | Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
WO2006033001A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
DE202005016343U1 (de) | 2005-10-19 | 2007-02-22 | Weidmüller Interface GmbH & Co. KG | Elektrische Steckverbindung mit Schnellentriegelung |
AU2006316605B2 (en) | 2005-11-17 | 2012-04-26 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
JP2009520028A (ja) | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Igfr抑制剤および抗癌剤の併用 |
EP1981890A2 (en) | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
EP1996193A2 (en) | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
AU2007267121A1 (en) | 2006-05-31 | 2007-12-06 | Galapagos N.V. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
TW200900070A (en) | 2007-02-27 | 2009-01-01 | Osi Pharm Inc | Combination cancer therapy |
EP2178563A2 (en) | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
WO2009009016A1 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
AU2008307634A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110046144A1 (en) | 2008-01-18 | 2011-02-24 | Mulvihill Mark J | Imidazopyrazinol derivatives for the treatment of cancers |
WO2009143051A1 (en) | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
CA2758297A1 (en) | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
JP2012526138A (ja) | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CA2796192A1 (en) | 2010-06-23 | 2011-12-29 | OSI Pharmaceuticals, LLC | Polymorphs of osi-906 |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
-
2010
- 2010-04-19 CA CA2752826A patent/CA2752826A1/en not_active Abandoned
- 2010-04-19 JP JP2012507282A patent/JP2012524119A/ja active Pending
- 2010-04-19 WO PCT/US2010/031547 patent/WO2010123792A1/en active Application Filing
- 2010-04-19 BR BRPI1016245-3A patent/BRPI1016245A2/pt not_active IP Right Cessation
- 2010-04-19 US US13/265,363 patent/US8513415B2/en not_active Expired - Fee Related
- 2010-04-19 CN CN2010800174272A patent/CN102405214A/zh active Pending
- 2010-04-19 MX MX2011011025A patent/MX2011011025A/es not_active Application Discontinuation
- 2010-04-19 EP EP10714546A patent/EP2421837A1/en not_active Withdrawn
- 2010-04-19 KR KR1020117020844A patent/KR20120020099A/ko not_active Application Discontinuation
-
2013
- 2013-05-23 US US13/901,054 patent/US20130261306A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673026A (ja) * | 1992-04-28 | 1994-03-15 | Koei Chem Co Ltd | クロロピラジン類の製造法 |
JP2006514075A (ja) * | 2002-11-20 | 2006-04-27 | バイエル・クロツプサイエンス・エス・アー | 2−アミノメチルピリジン誘導体の製造方法 |
JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
JP2007531754A (ja) * | 2004-04-02 | 2007-11-08 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
WO2007070826A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
JP2008105970A (ja) * | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
Non-Patent Citations (1)
Title |
---|
JPN7014001354; HARTZ,R. A.,ET AL.: '"Synthesis and Evaluation of Imidazo[1,5-a]pyrazines as Corticotropin Releasing Hormone Receptor Lig' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS VOL.12,NO.3, 2002, PP.291-294 * |
Also Published As
Publication number | Publication date |
---|---|
MX2011011025A (es) | 2011-11-02 |
US8513415B2 (en) | 2013-08-20 |
US20120041202A1 (en) | 2012-02-16 |
US20130261306A1 (en) | 2013-10-03 |
WO2010123792A1 (en) | 2010-10-28 |
EP2421837A1 (en) | 2012-02-29 |
BRPI1016245A2 (pt) | 2015-09-01 |
KR20120020099A (ko) | 2012-03-07 |
CA2752826A1 (en) | 2010-10-28 |
CN102405214A (zh) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012524119A (ja) | C−ピラジン−メチルアミンの調製 | |
JP6691115B2 (ja) | コパンリシブおよびそれの二塩酸塩の合成 | |
TWI697494B (zh) | 科帕利普(copanlisib)及其二鹽酸鹽之合成 | |
TWI426074B (zh) | 5-(2-胺基-嘧啶-4-基)-2-芳基-1h-吡咯-3-羧醯胺之製造方法 | |
US11708362B2 (en) | Process for preparing aminopyrimidine derivatives | |
US9890159B2 (en) | Process for making duocarmycin prodrugs | |
Heaner IV et al. | Indoles via Knoevenagel–Hemetsberger reaction sequence | |
JP2009137946A (ja) | β−アドレナリン受容体のアゴニストとして有用なアリールエタノールジアミンの製造方法 | |
JP2012532882A (ja) | 置換3−アミノ−5−オキソ−4,5−ジヒドロ−[1,2,4]トリアジンのための製法 | |
JP5570524B2 (ja) | 5−ホルミル−ピリジン−2,3−ジカルボン酸エステルの製造方法 | |
IL271974B (en) | New intermediates useful for the synthesis of aminopyrimidine derivatives, a process for their preparation and a process for preparing aminopyrimidine derivatives using them | |
WO2011093365A1 (ja) | 含窒素複素環化合物 | |
KR20200128707A (ko) | 가용성 구아닐레이트 시클라제 자극제의 제조 방법 | |
TWI830876B (zh) | 6-(1-丙烯醯基呱啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的製備工藝 | |
US8236954B2 (en) | Processes for preparing benzimidazole thiophenes | |
US20070293678A1 (en) | Process For The Preparation Of 6, 8-Subs Tituted '1, 7 Naphthpyridin Derivatives By Reacting The 8-Halo-'1, 7 Naphthpyrid In-Derivate With An Organic Boronic Acid Derivatives And Intermadiates Of This Process | |
Mamedov et al. | 3-(α-azidoalkyl) quinoxalin-2 (1H)-ones and related alkylquinoxalinyl ketones | |
CN111303160A (zh) | 一种取代吡咯并嘧啶中间体的制备方法 | |
CN115745956A (zh) | 一种3-溴-1-(3-氯-2-吡啶基)-1氢-吡唑-5-甲酸的合成方法 | |
EP3870568A1 (en) | Process for the preparation of rilpivirine | |
CN1290247A (zh) | 制备抗叶酸剂的方法和中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130306 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140502 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140715 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150123 |